Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

During COVID-19 vaccination campaign, possible ChAdOx1-S-associated risks of thrombosis with thrombocytopenia syndrome led to implement ChAdOx1-S/BNT162b2 heterologous vaccination, despite the limited information on its reactogenicity and safety. We conducted a prospective observational post-marketi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortunato, Francesca, Prato, Rosa, Iannelli, Giuseppina, Ascatigno, Leonardo, Loconsole, Daniela, Lopalco, Pier Luigi, Martinelli, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294748/
https://www.ncbi.nlm.nih.gov/pubmed/37226552
http://dx.doi.org/10.1080/21645515.2023.2209919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294748/
https://www.ncbi.nlm.nih.gov/pubmed/37226552
http://dx.doi.org/10.1080/21645515.2023.2209919

Ejemplares similares